Synapse - Hematologic Malignancies, Division of

Results (13375)

Post-Hoc analysis of measurable residual disease from BMT-CTN 1506/MORPHO: FLT3-ITD variant allele frequency and survival are highly correlated

Meeting Abstract

Levis, M. J.; Hamadani, M.; Logan, B. R.; Jones, R. J.; Singh, A. K.; Litzow, M. R.; Wingard, J. R.; Papadopoulos, E. B.; Perl, A.; Soiffer, R. J.; more...
Blood (2023)

Fulltext@MSK | Save

DNA methylation-based classification of hairy cell leukemia and splenic B cell lymphoma

Meeting Abstract

Yamaguchi, K.; Abdelbaky, S.; Arons, E.; Cross, M.; Wu, Y. Z.; Weigel, C.; Anghelina, M. I.; Parker, H.; Kibler, A.; Salido, M.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study

Meeting Abstract

Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib in post-cBTKi CLL/SLL: ∼30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study

Meeting Abstract

Woyach, J. A.; Brown, J. R.; Ghia, P.; Roeker, L. E.; Patel, K.; Eyre, T. A.; Munir, T.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
Blood (2023)

Fulltext@MSK | Save

Outcomes of patients with richter transformation without prior chemoimmunotherapy for CLL/SLL: An international multicenter retrospective study

Meeting Abstract

Kittai, A. S.; Huang, Y.; Miller, S.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E. A.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory marginal zone lymphoma: Results from phase 1/2 BRUIN study

Meeting Abstract

Patel, K.; Vose, J. M.; Nasta, S. D.; Brown, J. R.; Maddocks, K. J.; Woyach, J. A.; Shah, N. N.; Fakhri, B.; Tessoulin, B.; Ma, S.; more...
Blood (2023)

Fulltext@MSK | Save

Obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-cell acute lymphoblastic leukemia (R/R B-ALL): Pooled analysis of the ongoing FELIX phase Ib/II study

Meeting Abstract

Roddie, C.; Sandhu, K. S.; Tholouli, E.; Shaughnessy, P.; Barba, P.; Guerreiro, M.; Bishop, M. R.; Yared, J. A.; Ghobadi, A.; Yallop, D.; more...
Blood (2023)

Fulltext@MSK | Save

TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma

Meeting Abstract

Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
Blood (2023)

Fulltext@MSK | Save

The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: A prospective BMT-CTN study 1704

Meeting Abstract

Artz, A.; Logan, B. R.; Saber, W.; Geller, N.; Bellach, A.; Kou, J.; Wood, W.; McCarty, J. M.; Knight, T. G.; Runaas, L.; more...
Blood (2023)

Fulltext@MSK | Save

Pelabresib in combination with ruxolitinib for Janus Kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study

Meeting Abstract

Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
Blood (2023)

Fulltext@MSK | Save